\-\ Texto\\:\\ \ \(0\)\
\-\ urine\\ oxalate\\ of\\ 130\\ mg\\/day\ \(1\)\
\-\ improving\\ post\\ liver\\ transplant\ \(0\)\
\-\ \\â\\€\\¢\\ radiographs\\ of\\ the\\ spine\\ demonstrate\\ diffusely\\ increased\\ density\ \(0\)\
\-\ \\â\\€\\¢\\ the\\ kidneys\\ also\\ appear\\ hyperdense\\ \\(no\\ recent\\ iv\\ contrast\\ administration\\)\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ surgical\\ staples\\ consistent\\ with\\ recent\\ liver\\ transplant\\.\ \(0\)\
\-\ renal\\ oxalosis\ \(0\)\
\-\ \\â\\€\\¢\\ hyperdense\\ bones\\ \\(courtesy\\ dr\\.\\ clyde\\ helms\\)\\:\ \(0\)\
\-\ renal\\ osteodystrophy\\ \ \(4\)\
\-\ sickle\\ cell\\ disease\\ \ \(17\)\
\-\ myelofibrosis\\ \ \(1\)\
\-\ osteopetrosis\\ \ \(0\)\
\-\ pyknodysostosis\\ \ \(1\)\
\-\ mastocytosis\\ \ \(0\)\
\-\ metastases\\ \\-\\ breast\\ and\\ prostate\\ \ \(0\)\
\-\ paget\\ disease\\ \ \(0\)\
\-\ athletes\\ \ \(4\)\
\-\ fluorosis\ \(0\)\
\-\ 23\\ yo\\ man\\ who\\ has\\ a\\ history\\ of\\ recurrent\\ calcium\\ oxalate\\ nephrolithiasis\\ treated\\ with\\ pyridoxine\\.\\ \\ he\\ also\\ has\\ a\\ cardiac\\ arrythmia\\ and\\ recently\\ underwent\\ a\\ liver\\ transplant\\.\ \(0\)\
\-\ the\\ images\\ reveal\\ severe\\ cortical\\ nephrocalcinosis\\,\\ osteosclerosis\\,\\ and\\ renal\\ osteodystrophy\\.\\ \\ the\\ differential\\ diagnosis\\ for\\ cortical\\ nephrocalcinosis\\ includes\\ renal\\ cortical\\ necrosis\\,\\ chronic\\ or\\ hereditary\\ glomerulonephritis\\,\\ and\\ oxalosis\\,\\ and\\ renal\\ transplant\\ rejection\\.\\ \\ consider\\ why\\ this\\ young\\ patient\\ has\\ cortical\\ nephrocalcinosis\\ and\\ has\\ had\\ a\\ liver\\ transplant\\.\ \(0\)\
\-\ the\\ patient\\ clinically\\ has\\ primary\\ hyperoxaluria\\ \\(\\ urine\\ oxalate\\ \\>\\ 80\\ mg\\ \\/\\ day\\)\\.\\ \\ primary\\ hyperoxaluria\\ is\\ usually\\ divided\\ into\\ two\\ autosomal\\ recessive\\ diseases\\:\\ type\\ 1\\ \\(peroxisomal\\ liver\\ agt\\ enzyme\\ disorder\\)\\ and\\ type\\ 2\\ \\(cytosolic\\ enzyme\\ disorder\\)\\.\\ \\ usually\\ type\\ 2\\ hyperoxaluria\\ has\\ a\\ mild\\ clinical\\ course\\ \\(unlike\\ this\\ case\\)\\.\ \(0\)\
\-\ this\\ patient\\ has\\ type\\ 1\\ primary\\ hyperoxaluria\\ \\(ph1\\)\\ and\\ \\"oxalosis\\.\\"\\ \\ oxalosis\\ refers\\ to\\ calcium\\ oxalate\\ deposition\\ in\\ tissues\\ other\\ than\\ the\\ kidney\\ which\\ occurs\\ when\\ oxalateretention\\ due\\ to\\ renal\\ failure\\ is\\ added\\ to\\ oxalate\\ over\\-production\\ due\\ to\\ a\\ metabolic\\ condition\\.\ \(0\)\
\-\ ph1\\ is\\ caused\\ by\\ a\\ rare\\ inborn\\ error\\ in\\ liver\\ metabolism\\ \\(autosomal\\ recessive\\)\\ in\\ which\\ excessive\\ amounts\\ of\\ oxalic\\ acid\\ are\\ formed\\ which\\ combine\\ with\\ calcium\\ and\\ deposit\\ throughout\\ the\\ body\\ \\(kidney\\,\\ soft\\ tissue\\,\\ bone\\)\\.\\ \\ the\\ hepatic\\ peroxisomal\\ enzyme\\ agt\\ \\(alanine\\:glyoxylate\\ aminotransferase\\)\\ is\\ defective\\ and\\ glyoxylate\\ cannot\\ be\\ converted\\ into\\ glycine\\;\\ hence\\,\\ excessive\\ glyoxylate\\ is\\ metabolized\\ into\\ oxalate\\.\ \(0\)\
\-\ this\\ disorder\\ leads\\ to\\ progressive\\ renal\\ failure\\ secondary\\ to\\ cortical\\ nephrocalcinosis\\ which\\ usually\\ leads\\ to\\ early\\ death\\ in\\ childhood\\ unless\\ dialysis\\ is\\ instituted\\.\\ \\ common\\ radiographic\\ findings\\ in\\ oxalosis\\ include\\ dense\\ kidneys\\ \\(nephrocalcinosis\\)\\,\\ dense\\ bones\\ \\(calcium\\ oxalate\\ crystal\\ deposition\\ and\\ renal\\ osteodystrophy\\)\\,\\ soft\\ tissue\\ and\\ vascular\\ calcifications\\,\\ and\\ radiopaque\\ renal\\ calculi\\.\\ \\ treatment\\ includes\\ pyridoxine\\,\\ dialysis\\,\\ and\\ liver\\ transplant\\ to\\ replace\\ the\\ defective\\ agt\\ enzyme\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ oxalate\\:\\ 0\\.12393750265534836\ \(0\)\
\-\ oxalosis\\:\\ 0\\.09978343050868001\ \(0\)\
\-\ hyperoxaluria\\:\\ 0\\.0758418293395419\ \(0\)\
\-\ nephrocalcinosis\\:\\ 0\\.07349269139938922\ \(0\)\
\-\ transplant\\:\\ 0\\.06959961466945058\ \(0\)\
\-\ enzyme\\:\\ 0\\.06620222980134312\ \(0\)\
\-\ glyoxylate\\:\\ 0\\.06497925128230835\ \(0\)\
\-\ agt\\:\\ 0\\.05987005830520801\ \(0\)\
\-\ liver\\:\\ 0\\.05067211443692645\ \(0\)\
\-\ renal\\:\\ 0\\.05046634986649767\ \(0\)\
\-\ ph1\\:\\ 0\\.043319500854872225\ \(0\)\
\-\ osteodystrophy\\:\\ 0\\.041553793073355424\ \(0\)\
\-\ calcium\\:\\ 0\\.041088839663261545\ \(0\)\
\-\ pyridoxine\\:\\ 0\\.039913372203472006\ \(0\)\
\-\ peroxisomal\\:\\ 0\\.039913372203472006\ \(0\)\
\-\ cortical\\:\\ 0\\.038268732808056656\ \(0\)\
\-\ defective\\:\\ 0\\.03792091466977095\ \(0\)\
\-\ type\\:\\ 0\\.02831080322699666\ \(0\)\
\-\ disorder\\:\\ 0\\.028295710183385187\ \(0\)\
\-\ recessive\\:\\ 0\\.0279116668699624\ \(0\)\
\-\ has\\:\\ 0\\.02759926239179348\ \(0\)\
\-\ dialysis\\:\\ 0\\.026288857597871113\ \(0\)\
\-\ excessive\\:\\ 0\\.025444384590860503\ \(0\)\
\-\ autosomal\\:\\ 0\\.02429640006417006\ \(0\)\
\-\ deposition\\:\\ 0\\.023451927057159448\ \(0\)\
\-\ leads\\:\\ 0\\.023451927057159448\ \(0\)\
\-\ \\-myelofibrosis\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ \\-osteopetrosis\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ \\-pyknodysostosis\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ \\-mastocytosis\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ \\-athletes\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ \\-fluorosis\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ cytosolic\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ oxalateretention\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ over\\-production\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ oxalic\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ alanine\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ glycine\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ metabolized\\:\\ 0\\.021659750427436113\ \(0\)\
\-\ \\(\\:\\ 0\\.02129813443470842\ \(0\)\
\-\ \\)\\:\\ 0\\.02103796635223504\ \(0\)\
\-\ hyperdense\\:\\ 0\\.02099372796902454\ \(0\)\
\-\ urine\\:\\ 0\\.02026619430829167\ \(0\)\
\-\ mg\\/day\\:\\ 0\\.019956686101736003\ \(0\)\
\-\ \\-sickle\\:\\ 0\\.019956686101736003\ \(0\)\
\-\ inborn\\:\\ 0\\.019956686101736003\ \(0\)\
\-\ aminotransferase\\:\\ 0\\.019956686101736003\ \(0\)\
\-\ dense\\:\\ 0\\.01983486452508584\ \(0\)\
\-\ kidneys\\:\\ 0\\.019325388213170158\ \(0\)\
\-\ usually\\:\\ 0\\.019127235286487167\ \(0\)\
\-\ staples\\:\\ 0\\.018960457334885474\ \(0\)\
\-\ clyde\\:\\ 0\\.018960457334885474\ \(0\)\
\-\ \\-paget\\:\\ 0\\.018960457334885474\ \(0\)\
\-\ primary\\:\\ 0\\.01865885206065624\ \(0\)\
\-\ arrythmia\\:\\ 0\\.01825362177603589\ \(0\)\
\-\ combine\\:\\ 0\\.01825362177603589\ \(0\)\
\-\ bones\\:\\ 0\\.01772006030036893\ \(0\)\
\-\ \\-metastases\\:\\ 0\\.017705357522192624\ \(0\)\
\-\ rejection\\:\\ 0\\.017705357522192624\ \(0\)\
\-\ courtesy\\:\\ 0\\.017257393009185364\ \(0\)\
\-\ osteosclerosis\\:\\ 0\\.017257393009185364\ \(0\)\
\-\ error\\:\\ 0\\.017257393009185364\ \(0\)\
\-\ includes\\:\\ 0\\.01692815919331123\ \(0\)\
\-\ 130\\:\\ 0\\.01687864441010119\ \(0\)\
\-\ converted\\:\\ 0\\.01687864441010119\ \(0\)\
\-\ replace\\:\\ 0\\.01687864441010119\ \(0\)\
\-\ failure\\:\\ 0\\.016449426451259786\ \(0\)\
\-\ \\-renal\\:\\ 0\\.016261164242334834\ \(0\)\
\-\ deposit\\:\\ 0\\.01600229319649251\ \(0\)\
\-\ instituted\\:\\ 0\\.01576811585053594\ \(0\)\
\-\ which\\:\\ 0\\.01567709668051645\ \(0\)\
\-\ glomerulonephritis\\:\\ 0\\.015554328683485252\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.015400632448116834\ \(0\)\
\-\ into\\:\\ 0\\.014987663645894645\ \(0\)\
\-\ added\\:\\ 0\\.014847493124635668\ \(0\)\
\-\ kidney\\:\\ 0\\.014793039091154838\ \(0\)\
\-\ why\\:\\ 0\\.014698538279877842\ \(0\)\
\-\ amounts\\:\\ 0\\.014698538279877842\ \(0\)\
\-\ radiopaque\\:\\ 0\\.014698538279877842\ \(0\)\
\-\ helms\\:\\ 0\\.014558099916634726\ \(0\)\
\-\ refers\\:\\ 0\\.014558099916634726\ \(0\)\
\-\ crystal\\:\\ 0\\.0142992288707924\ \(0\)\
\-\ recent\\:\\ 0\\.014116555522554286\ \(0\)\
\-\ improving\\:\\ 0\\.014065051524835828\ \(0\)\
\-\ dr\\:\\ 0\\.014065051524835828\ \(0\)\
\-\ calculi\\:\\ 0\\.014065051524835828\ \(0\)\
\-\ hence\\:\\ 0\\.013750964616949133\ \(0\)\
\-\ metabolism\\:\\ 0\\.013654599228366131\ \(0\)\
\-\ divided\\:\\ 0\\.01322243542870111\ \(0\)\
\-\ unlike\\:\\ 0\\.01322243542870111\ \(0\)\
\-\ formed\\:\\ 0\\.012995473954177732\ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.012361987199135716\ \(0\)\
\-\ acid\\:\\ 0\\.012306771337091347\ \(0\)\
\-\ hereditary\\:\\ 0\\.012047900291249022\ \(0\)\
\-\ childhood\\:\\ 0\\.011813722945292449\ \(0\)\
\-\ mg\\:\\ 0\\.011519371103000999\ \(0\)\
\-\ consider\\:\\ 0\\.011403270648822753\ \(0\)\
\-\ unless\\:\\ 0\\.011365758432285189\ \(0\)\
\-\ death\\:\\ 0\\.011328810330652413\ \(0\)\
\-\ due\\:\\ 0\\.011205293134903389\ \(0\)\
\-\ prostate\\:\\ 0\\.011151971265234503\ \(0\)\
\-\ diffusely\\:\\ 0\\.010603707011391236\ \(0\)\
\-\ diseases\\:\\ 0\\.010576557536731323\ \(0\)\
\-\ \\/\\:\\ 0\\.010369529665434665\ \(0\)\
\-\ metabolic\\:\\ 0\\.010369529665434665\ \(0\)\
\-\ soft\\:\\ 0\\.010225684343948648\ \(0\)\
\-\ 1\\:\\ 0\\.009991775763929763\ \(0\)\
\-\ 23\\:\\ 0\\.009980167648304996\ \(0\)\
\-\ tissue\\:\\ 0\\.009952929672985718\ \(0\)\
\-\ 80\\:\\ 0\\.009876481273635766\ \(0\)\
\-\ recently\\:\\ 0\\.009796571711705645\ \(0\)\
\-\ this\\:\\ 0\\.009446065978517278\ \(0\)\
\-\ reveal\\:\\ 0\\.009348607198698384\ \(0\)\
\-\ clinically\\:\\ 0\\.009205440348270925\ \(0\)\
\-\ young\\:\\ 0\\.00914439366869714\ \(0\)\
\-\ 2\\:\\ 0\\.009042282538135361\ \(0\)\
\-\ recurrent\\:\\ 0\\.008860030150184465\ \(0\)\
\-\ caused\\:\\ 0\\.008806903702977669\ \(0\)\
\-\ condition\\:\\ 0\\.008780765132449277\ \(0\)\
\-\ hepatic\\:\\ 0\\.008767799390186761\ \(0\)\
\-\ administration\\:\\ 0\\.008716609987477076\ \(0\)\
\-\ \\,\\:\\ 0\\.008646758849446526\ \(0\)\
\-\ tissues\\:\\ 0\\.008617323652494577\ \(0\)\
\-\ occurs\\:\\ 0\\.008617323652494577\ \(0\)\
\-\ appear\\:\\ 0\\.008593116535926983\ \(0\)\
\-\ to\\:\\ 0\\.008394459134014471\ \(0\)\
\-\ \\:\\:\\ 0\\.008331263999931192\ \(0\)\
\-\ progressive\\:\\ 0\\.008298376204037599\ \(0\)\
\-\ is\\:\\ 0\\.00828929894424657\ \(0\)\
\-\ necrosis\\:\\ 0\\.00828771674065038\ \(0\)\
\-\ also\\:\\ 0\\.008278228961524085\ \(0\)\
\-\ rare\\:\\ 0\\.00815319459133488\ \(0\)\
\-\ cardiac\\:\\ 0\\.007997141997422531\ \(0\)\
\-\ radiographic\\:\\ 0\\.007968954279579199\ \(0\)\
\-\ course\\:\\ 0\\.00792268167925219\ \(0\)\
\-\ throughout\\:\\ 0\\.00785933004004896\ \(0\)\
\-\ calcifications\\:\\ 0\\.007806299151431824\ \(0\)\
\-\ breast\\:\\ 0\\.0077458426138342805\ \(0\)\
\-\ early\\:\\ 0\\.007678523266934736\ \(0\)\
\-\ iv\\:\\ 0\\.007661977733319641\ \(0\)\
\-\ underwent\\:\\ 0\\.007204412863582848\ \(0\)\
\-\ \\>\\:\\ 0\\.006975841559382222\ \(0\)\
\-\ spine\\:\\ 0\\.006914259326794466\ \(0\)\
\-\ density\\:\\ 0\\.006908185151990071\ \(0\)\
\-\ vascular\\:\\ 0\\.006884037513326035\ \(0\)\
\-\ disease\\:\\ 0\\.006863575141109111\ \(0\)\
\-\ a\\:\\ 0\\.006821126812604936\ \(0\)\
\-\ body\\:\\ 0\\.006818829760906841\ \(0\)\
\-\ differential\\:\\ 0\\.006665748966469114\ \(0\)\
\-\ day\\:\\ 0\\.006665748966469114\ \(0\)\
\-\ radiographs\\:\\ 0\\.006649314106147746\ \(0\)\
\-\ post\\:\\ 0\\.006611388287646913\ \(0\)\
\-\ severe\\:\\ 0\\.006460220638982811\ \(0\)\
\-\ clinical\\:\\ 0\\.006460220638982811\ \(0\)\
\-\ yo\\:\\ 0\\.0063178170105718965\ \(0\)\
\-\ patient\\:\\ 0\\.006313945436730133\ \(0\)\
\-\ treated\\:\\ 0\\.0062846457889038304\ \(0\)\
\-\ and\\:\\ 0\\.006191955971132822\ \(0\)\
\-\ two\\:\\ 0\\.00601309886392139\ \(0\)\
\-\ when\\:\\ 0\\.00601309886392139\ \(0\)\
\-\ chronic\\:\\ 0\\.005913979442031941\ \(0\)\
\-\ include\\:\\ 0\\.005889812009902424\ \(0\)\
\-\ secondary\\:\\ 0\\.005869852497564637\ \(0\)\
\-\ he\\:\\ 0\\.005857954157329286\ \(0\)\
\-\ cell\\:\\ 0\\.005671353099708811\ \(0\)\
\-\ mild\\:\\ 0\\.005528878265187069\ \(0\)\
\-\ than\\:\\ 0\\.005501348537882736\ \(0\)\
\-\ common\\:\\ 0\\.0054945140342909015\ \(0\)\
\-\ who\\:\\ 0\\.005474123855385017\ \(0\)\
\-\ bone\\:\\ 0\\.00521728422963113\ \(0\)\
\-\ in\\:\\ 0\\.0051768701491431805\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.005160036947498322\ \(0\)\
\-\ consistent\\:\\ 0\\.005148152994671261\ \(0\)\
\-\ increased\\:\\ 0\\.005136326245207999\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.005060809587179958\ \(0\)\
\-\ \\;\\:\\ 0\\.004976464836492859\ \(0\)\
\-\ man\\:\\ 0\\.004965434503906632\ \(0\)\
\-\ other\\:\\ 0\\.004839406753568669\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0048315777428330235\ \(0\)\
\-\ diagnosis\\:\\ 0\\.004821177716905208\ \(0\)\
\-\ can\\:\\ 0\\.004762217082233586\ \(0\)\
\-\ contrast\\:\\ 0\\.004699694562181585\ \(0\)\
\-\ case\\:\\ 0\\.004593376984931869\ \(0\)\
\-\ had\\:\\ 0\\.004530343536217956\ \(0\)\
\-\ \\-\\:\\ 0\\.004500561323607773\ \(0\)\
\-\ findings\\:\\ 0\\.004468886820122751\ \(0\)\
\-\ surgical\\:\\ 0\\.004413321302829124\ \(0\)\
\-\ treatment\\:\\ 0\\.004249673119412499\ \(0\)\
\-\ images\\:\\ 0\\.004027675410194973\ \(0\)\
\-\ by\\:\\ 0\\.0034959973052699623\ \(0\)\
\-\ be\\:\\ 0\\.0032377315069875407\ \(0\)\
\-\ the\\:\\ 0\\.003057109489760767\ \(0\)\
\-\ not\\:\\ 0\\.0030339525104224455\ \(0\)\
\-\ history\\:\\ 0\\.0028997900189363227\ \(0\)\
\-\ are\\:\\ 0\\.002862097966903198\ \(0\)\
\-\ or\\:\\ 0\\.0024607438549476843\ \(0\)\
\-\ no\\:\\ 0\\.002114113392392634\ \(0\)\
\-\ for\\:\\ 0\\.0017914205126356637\ \(0\)\
\-\ \\.\\:\\ 0\\.0015700040534452897\ \(0\)\
\-\ of\\:\\ 0\\.0011450004992431294\ \(0\)\
\-\ with\\:\\ 0\\.0008624386443972217\ \(0\)\
